I am thinking JNJ may purchase Dexcom.
Historically JNJ will work with a partner only to purchase them at a later date.
JNJ / Animas is working with Dexcom currently.
Continous monitoring eliminates the need for strips and eliminates the pain of lancing skin up to 7 times per day.
Conventional glucose monitors that require costly strips and lancing device will be replaced by Continous meters in the future.
I take an educated guess and would expect Dexcom has the potential to sell in the triple digits.
From Forbes: The business of glucose monitoring is growing at a fast rate of 25% annually, and experts estimate that by 2017, the market will exceed $30 billion worldwide
• JNJ acquired Inverness Medical Technology's Diabetes Care Products Business in $1.3 Billion Stock-for-Stock Transaction.
• JNJ purchased Animas Corp with a cash-for-stock agreement, worth approximately $518 million.
• JNJ purchased privately held Lifescan 1986.